Kornimate/medical-research-clean huggingface dataset:
antiplatelet therapy after cardiac arrest

Conditions: Cardiac Arrest; Postresuscitation Syndrome; Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)

Summary: there is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid (asa) and clopidogrel is not as effective in the setting of therapeutic hypothermia after cardiac arrest as in normothermic patients. the reasons for this are probably slower gastrointestinal motility, absorption and liver metabolism required for clopidogrel to take action. since ticagrelor has faster intestinal absorption and no need for liver metabolism we expect its effect to be good even in patients with therapeutic hypothermia after cardiac arrest. patients treated with therapeutic hypothermia after cardiac arrest and percutaneous coronary intervention will be randomised into two groups. one will be treated with asa and clopidogrel and the other with asa and ticagrelor. blood samples will be collected before and 2, 4, 12, 22 and 48 hours after p2y12 inhibitor administration. platelet function will be measured by verifynow p2y12 assay and by multiplate adptest. differences between the groups will be analysed. hypothesis: antiplatelet therapy with ticagrelor is more effective than therapy with clopidogrel in the comatose survivors of cardiac arrest treated with therapeutic hypothermia and percutaneous coronary intervention (pci).


Eligibility criteria:
inclusion criteria: * female and male over 18 years old * unconscious survivors of cardiac arrest treated with therapeutic hypothermia * acute coronary syndrome (nstemi or stemi) as a reason of cardiac arrest * pci with stent implantation * provision of informed consent prior to any study specific procedures is impossible because subjects are unconscious at the moment of inclusion exclusion criteria: * use of any p2y12 inhibitors in last 10 days * use of prasugrel before and 48 hours after loading dose of p2y12 inhibitor * use of eptifibatide before and 48 hours after loading dose of p2y12 inhibitor * thrombocytopenia (\<50\*109/l) * allergic reaction to acetylsalicylic acid, clopidogrel or ticagrelor * ticagrelor contraindications: previous intracranial bleeding, active pathological bleeding, moderate to severe hepatic impairment, heart rate \< 40/min at presentation * suspected or confirmed pregnancy * use of bivalirudin before and 48 hours after loading dose of p2y12 inhibitor

Keywords: antiplatelet therapy cardiac arrest therapeutic hypothermia myocardial infarction (st-elevation myocardial infarction and non-st-elevation myocardial infarction)
clinical evaluation of poreskin

Conditions: Treatment

Summary: poreskin, a human acellular dermal matrix (hadm) manufactured by faculty of medicine, chulalongkorn university, is the first human dermal substitute developed in thailand. it is a permanent dermal substitute aiming to reduce skin contracture. the objective of this study is to assess the safety and ability in achieving durable and cosmetic coverage of poreskin.


Eligibility criteria:
inclusion criteria: * male and female patients * 18-60 years with burn scar contracture and hypertrophic scar exclusion criteria: * undergoing immunosuppressive therapy * immunocompromise host (dm, hiv infected) * evidence of malnutrition * active malignancy

Keywords: human acellular dermal matrix, burns, wound healing
speech perception training: advanced scoring and feedback methods

Conditions: Hearing Loss

Summary: the purpose of the study is to assess training of visual speech (lipreading) and audiovisual (lipreading plus auditory) speech as a rehabilitation strategy for hearing loss in adults.

it is hypothesized that training that improves lipreading in older adults can carry over to untrained lipreading materials and to audiovisual speech recognition in noise. participants receive pre- and post-training tests of speech recognition with visual-only, auditory-only, and audiovisual spoken sentences and isolated words. during pre- and post-training tests, they carry out forced choice identification of lipread consonants. participants who are assigned to a training arm train on lipreading isolated sentences (aim 1) or on learning via lipreading sets of isolated nonsense words (aim 2). depending on the outcomes of aims 1 and 2, in aim 3, new participants receive audiovisual training with conditions from aims 1 and 2.

Eligibility criteria:
inclusion criteria: * must have mild to severe hearing loss * native speaker of american english * access to computer and the ability to use it for the testing, training, and teleconferencing * computer display \>= 10 inches diagonal exclusion criteria: * internet too slow for streaming * history of brain trauma or learning disability * poor (corrected) vision

Keywords: lipreading speechreading perceptual learning adults with acquired hearing loss multisensory speech processing remote training system speech recognition in noise perceptual feedback during training
characterizing mymood patterns of use

Conditions: Bipolar Disorder; Mood Disorders; Depression; Dysthymia

Summary: mymood is an electronic mood-charting tool available to the general population of sunnybrook health sciences centre (shsc). this project aims to characterize duration and frequency of use of mymood by users characteristics and determine if there is any significant variability in duration and frequency of use attributable to users' age, sex, self-reported diagnosis of a mood disorder, and/or prior treatment.

mental health telemetry (mht) is a software platform developed at sunnybrook for collecting real-time self-report symptom-rating questionnaire data using patients' cell phones or other portable, internet-enabled devices. mht has previously been used in several funded clinical research studies. the mood-disorders-specific version of mht, which we have named mymood, collects information on a variety of items including symptom severity, medication adherence, er visits / hospital admissions, sleep, relationships, and life events. in our previous project, we made mymood available to the general population of shsc by integrating it into sunnybrook's mychart personal health record system and collected feedback from users, using the feedback to refine mymood. in the current project, we aim to characterize long-term patterns of mymood usage, examining how duration and frequency of use are affected by demographic and clinical characteristics of users (age, sex, present / reported diagnosis of a mood disorder, and/or prior treatment). please note that the _only_ route for entry into this study is self-referral: interested individuals who have signed themselves up for mychart can choose to begin using mymood on their own. there is no reason to contact the study team regarding recruitment.

Eligibility criteria:
inclusion criteria: • registered user of sunnybrook health sciences centre "mychart" electronic patient portal exclusion criteria: • n/a
grace - study of agn1 loep in osteopenic and osteoporotic patients

Conditions: Osteoporosis

Summary: the study is designed as a retrospective, single-center study for subjects previously treated with the agn1 loep kit. this will be a non-randomized and non-blinded study. the study will collect retrospective data on the safety and performance of agn1 loep of all subjects treated outside of any other clinical study protocols between september 2019 and november 2022. a prospective questionnaire will be included to evaluate self-reported subject experiences.


Eligibility criteria:
inclusion criteria: * subject has previously received agn1 loep treatment between september 2019 and november 2022. * subject has willingness to participate in the study. * subject can give written informed consent to allow for data collection. exclusion criteria: * the subject's agn1 loep treatment was previously performed as part of a prior protocoled clinical study.

Keywords: bone mineral density femoral strength hip fracture local osteo-enhancement procedure loep proximal femur
quality-assured follow-up of quiescent neovascular age -related macular degeneration by non-medical practitioners

Conditions: AMD

Summary: this is a prospective, randomised, multi-site clinical trial testing the non-inferiority of community optometry follow-up of participants with qnamd over 12 months

neovascular age-related macular degeneration (namd) is a common vision threatening condition affecting mainly patients over the age of 65. at some point during follow-up the disease becomes inactive in many cases and does not need more injections. the risk of a flare-up is high, however, and patients need to continue to be seen every month for a significant period of time. hospital-based eye clinics are struggling to cope with current and expected workload for assessing and treating patients with namd. transferring care of these patients to the community closer to home would ease the workload for hospital based clinics and offer a better experience of care to patients. this study will recruit 742 patients with namd who have reached this inactive phase of the disease. half of the patients that want to take part will continue to have their follow-up appointments in the hospital eye clinics as usual. the other half, chosen by chance, will have follow-up visits every month in a community optometrist practice by trained optometrists. the research team will provide the training for community optometrists. the study will seek to show that the community based care is no less safe than hospital-based care. the study will also check what is the impact of this different way of offering care on the nhs budget and how the patients and practitioners perceive this. the study will involve several hospital eye clinics across the country and several community optometrist practices. meetings will also be held with patients to discuss their priorities and needs when looking at how to set up the community based eye clinics. during meetings with patients in preparation for this research, they felt positively about the possibility to receive care closer to home.

Eligibility criteria:
inclusion criteria: * participants receiving treatment in namd injection clinics, who have reached the agreed definition of disease quiescence * informed consent * aged \> 55 years * ability to perform study specific procedures exclusion criteria: * significant media opacities (cataract, vitreous opacities) that would not allow good quality fundus imaging. * diabetic retinopathy of severity worse than mild non-proliferative stage and with any degree of diabetic maculopathy * history of other causes of choroidal neovascularisation (myopic, angioid streaks, inflammatory, retinal dystrophies, secondary to central serous chorioretinopathy, idiopathic).

Keywords: amd namd
tcm syndrome differentiation treatment on discharged elderly patients with cap

Conditions: Community-acquired Pneumonia

Summary: this study is to evaluate the efficacy and safety of tcm syndrome differentiation treatment on the rehospitalization rate of discharged elderly patients with community acquired pneumonia(cap)and to explore its mechanism.

the incidence and mortality of elderly patients with cap are on a rising trend, especially the mortality of those over 65 years old are the highest. the elderly patients with cap have more complications and drug resistance, which makes it difficult to treat and have heavy burden on the society. the discharged elderly patients with cap are still facing the risk of readmission or even death due to recurrent pneumonia or other reasons. research reports showed that tcm syndrome differentiation treatment had a certain role in improving the condition of discharged elderly patients with cap. our previous exploratory studies suggested that tcm syndrome differentiation treatment on the discharged elderly patients with cap had good clinical efficacy and safety. this is a multi-center, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of tcm syndrome differentiation on the rehospitalization rate of discharged elderly patients with cap and to explore its mechanism. 292 patients will be randomly assigned in a 1:1 ratio to experimental group or control group for 2 months treatment and 6 months follow-up.the experimental group will be given by bu fei jian pi hua tan granule or yi qi yang yin qing fei granule based on tcm syndrome differentiation. the primary outcomes are rehospitalization rate. the secondary outcomes include mortality, assessment of disease severity(curb65 scores),quality of life (sf-36), treatment satisfaction(esq-cap),clinician reported outcome for cap,patient reported outcome for cap,nutritional status (mna-sf).

Eligibility criteria:
inclusion criteria: 1. a confirmed diagnosis of discharged elderly patients with cap within 1 weeks; 2. syndrome differentiation meets criteria of syndrome of the lung and spleen qi deficiency and unclean phlegm dampness, syndrome of qi and yin deficiency and unclean phlegm heat; 3. age including or above 65 years old; 4. voluntary treatment, oral medication; 5. with informed consent signed. exclusion criteria: 1. a confirmed diagnosis of discharged elderly patients with severe cap; 2. patients with unconscious, dementia or mental disorders; 3. patients with hydrothorax, bronchiectasis, active pulmonary tuberculosis, pulmonary abscess, chronic obstructive pulmonary disease of gold d; 4. patients with aspiration risk of severe neuromuscular disorders and long-term bedridden; 5. patients with tumor, severe cardiovascular disease and severe liver and kidney diseases; 6. participants in clinical trials of other drugs; 7. people who are allergic to the treatment drugs.

Keywords: the discharged elderly patients with cap syndrome differentiation of tcm randomized controlled trail
the impact of misclassification of obesity by body mass index on mortality in patients with chronic kidney disease

Conditions: Chronic Kidney Diseases; Obesity

Summary: unlike the general population, a higher body mass index (bmi) is associated with greater survival among patients with chronic kidney disease (ckd). however, obesity is defined as excess body fat that associated with clearly elevated health risks according to the world health organization. in addition, muscle wasting is prevalent among ckd subjects. thus, we hypothesized that different definition of obesity, based on bmi or body fat percentage, might have different impact on clinical outcomes among ckd population.


Eligibility criteria:
inclusion criteria: * subjects with non-dialysis ckd defined as estimated glomerular filtration rate (egfr) \<60 ml/min/1.73 m2 exclusion criteria: * subjects with liver cirrhosis * subjects with malignancy * subjects with an acute cardiovascular event within the 3 months before screening for inclusion * amputee * pregnancy * subjects with pacemaker * subjects with metallic implant

Keywords: diagnostic discordance of obesity all-cause mortality
investigating dynamic interactions in distributed cognitive control networks

Conditions: Cognitive Impairment; Dementia; ADD; Depression

Summary: the purpose of this study is to investigate the brain activity associated with cognitive tasks (thinking, reasoning, remembering) in order to understand how the brain works during certain tasks and to improve treatment for diseases like dementia and attention deficit disorders. cognitive (thinking) impairment may include poor memory function, poor attention span, or psychiatric disorders (ex: add, depression). the investigators are interested in the brain activity related to these issues, and want to investigate changes in brain activity while we record activity from specific areas of the brain. these recordings are in addition to clinical (routine or standard of care) recordings being performed to monitor for seizures and do not impact the clinical care.

routine intracranial monitoring (icm) surgery involves placement of several (10-20) electrodes into the brain through a small opening to a target structure. participants have been deemed a surgical candidate for this procedure, and detailed discussion of the procedure will occur as part of the surgical consent. the investigators may place sensors (stickers) to monitor participant's arm/hand movements and brain activity. sensors may be placed on participant's scalp and/or arms and legs. the investigators may place a device on participant's wrist or finger to measure position (accelerometer). the investigators may perform voice recordings, eye movement tracking, and motion capture recordings to obtain measures of how stimulation affects speech and other movements. these are performed without any attachment of devices. cognitive tasks: multiple cognitive tasks may be used and will be decided upon based on the clinical symptoms, exam, or comorbidities. these may include go/no-go, simon/stroop task, stop-signal task, language tasks, tower of london, gambling task, maze navigation, choice-reaction time, delay tasks, and attention tasks. cortico-cortical evoked potentials and patterned stimulation: stimulus pulses at precise time intervals and or various patterns will be delivered across adjacent electrode contacts at a series of electrode sites while simultaneously recording neural activity at other electrodes. this does not require any activity from participant. tasks will be administered via computer monitor positioned in front of the you. this will be connected to a recording computer. participant will respond via keyboard, mouse, or response button.

Eligibility criteria:
inclusion criteria: * eligible for surgery based on multi-disciplinary consensus review * have a diagnosis of medically-refractory epilepsy * a minimum of 18 years of age * willingness to participate in the paradigms described in the protocol exclusion criteria: * inability to provide full and informed consent * age younger than 18 * are not physically able to participate in study-related activities * major medical or surgical complication

Keywords: cognitive tasks epilepsy intracranial eeg
biomechanical and microstructural properties of ascending aortic aneurysms

Conditions: Thoracic Aortic Aneurysms

Summary: an aortic aneurysm (thoracic or abdominal) is a permanent dilatation of the aorta caused by weakening in the arterial wall. the feared complication is aortic rupture or dissection, leading to potentially lethal aortic bleeding and associated with mortality rates up to 95%. the current diagnosis criteria do not suffice, therefore the goal of this study is the development of an improved biomechanics-based and microstructural-based diagnostic tool.

an aortic aneurysm (thoracic or abdominal) is a permanent dilatation of the aorta caused by weakening in the arterial wall. the feared complication is aortic rupture or dissection, leading to potentially lethal aortic bleeding and associated with mortality rates up to 95%. diagnosis of the aneurysm and especially its risk of rupture or dissection is highly challenging. if the aneurysm diameter and/or growth rate exceed a specific threshold (respectively 55 mm and 1 cm/year), a highly invasive and dangerous surgery is performed. however, several studies have shown no correlation between the maximum transverse diameter and the risk of rupture or dissection. since aneurysm rupture is associated with multiple aortic tissue properties, both biomechanics-based and microstructurally-based criteria can be a promising alternative. the overall goal of this trial is a biomechanical and microstructural analysis of aneurysms to improve the diagnostic criterion for aneurysm rupture risk. within this goal, two scientific objectives can be distinguished. firstly, a highly unique dataset with patient data allowing the development of an improved diagnostic tool will be created. this dataset will contain an abundance of relevant parameters such as patient characteristics, geometry, material properties and biomechanical and microstructural characteristics. the biomechanical and microstructural data will be obtained by the analysis of resected aneurysmal tissue and by dynamic imaging (4d ct). 4d ct scans are a series of ecg-gated scans that are taken at specified intervals in the cardiac circle. the second objective is to create a personalized diagnostic tool. an aneurysm rupture risk criteria based on geometry as well as biomechanical and microstructural properties is expected to be significantly more reliable than the current criteria. more specifically, a correlation between patient characteristics that can be measured non-invasively and the aneurysm rupture risk is searched for.

Eligibility criteria:
inclusion criteria: * patients suffering from thoracic aortic aneurysms (ataa), asymptomatic or symptomatic. * patients with ruptured ataa undergoing an emergency surgery. * signed informed consent. exclusion criteria: * patients with ruptured ataa due to trauma. * the presence of any aneurysm feature that will prevent the collection of tissue samples suitable for the biomechanical and microstructural studies.

Keywords: improve diagnosis
dorado-ex: long-term safety extension study to the phase 3 dorado study (protocol dar-311) of darusentan in resistant hypertension

Conditions: Hypertension

Summary: this is a research study of a new experimental drug called darusentan. darusentan is not currently approved by the united states (u.s.) food and drug administration (fda) for use in the u.s., which means that a doctor cannot prescribe this drug. the purpose of this study is to evaluate the long-term safety of darusentan in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive medications, including a diuretic.


Eligibility criteria:
inclusion criteria: * subjects who have completed the treatment period of clinical trial dar-311 * receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic exclusion criteria: * subjects who discontinued treatment with study drug prior to the end of the treatment period of dar-311 due to a study drug-related adverse event (ae) * treatment with another endothelin receptor antagonist within 6 months of study entry

Keywords: resistant hypertension
role of the gut sweet taste receptor in the secretion of satiation peptides

Conditions: Taste Disorder, Secondary, Sweet

Summary: the purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of gastrointestinal (gi) satiation peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gastrointestinal tract.

there is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. it is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (glp-1) and peptide yy (pyy). several nutrient responsive g-protein coupled receptors have been identified in the human gut, including the sweet taste responsive t1r2/t1r3 heterodimer, the amino acid/umami responsive t1r1/t1r3 as well as gpr120 for unsaturated long-chain free fatty acids. the functional significance of sweet taste receptors in mixed liquid meal-stimulated secretion of glp-1 and pyy will be determined by intragastric infusion of a 500 ml mixed liquid meal with or without lactisole (450 ppm)in a double blind, 2-way crossover trial including 16 healthy subjects.

Eligibility criteria:
inclusion criteria: * healthy subjects * bmi of 19.0-24.5 * age 18-40 years old * stable body weight for at least 3 month exclusion criteria: * smoking * substance abuse * regular intake of medication * medical or psychiatric illness * gastrointestinal disorders or food allergies

Keywords: t1r2/t1r3 gastric emptying gut lactisole nutrient sensing